{"schema_version":"secwatch.filing_event.v1","accession":"0001326732-23-000028","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.586413+00:00","generated_at":"2026-06-10T13:09:18.003275+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Xencor adds Barbara Klencke, M.D., to board; board expands to eight members","bullets":["Board increased from 7 to 8 members; Dr. Klencke appointed effective Sept 15, 2023.","Dr. Klencke receives initial stock option with Black-Scholes value of $550,000, vesting over 3 years.","Annual cash retainer of $50,000 for board service; standard indemnification agreement.","Dr. Klencke previously CMO and CDO at Sierra Oncology; led Ojjaara approval for myelofibrosis.","Also serves on boards of eFFECTOR Therapeutics, Immune-Onc Therapeutics, and TScan Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001326732-23-000028","json":"https://secwatch.observer/filing/0001326732-23-000028.json","markdown":"https://secwatch.observer/filing/0001326732-23-000028.md","text":"https://secwatch.observer/filing/0001326732-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/0001326732-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/xncr-20230915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:09:18.003275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6189d473c7","claim":"Barbara Klencke was appointed as Director at Xencor Inc.","evidence_excerpt":"On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/0001326732-23-000028-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}